[{"id":"ff92b6e0-dfa4-4a74-a7db-5dface0e8ad1","acronym":"","url":"https://clinicaltrials.gov/study/NCT03894150","created_at":"2021-01-18T19:10:53.369Z","updated_at":"2024-07-02T16:35:04.030Z","phase":"Phase 1","brief_title":"A Study of F0002-ADC in Chinese Patients With Refractory or Recurrent CD30+ Hematologic Malignancies.","source_id_and_acronym":"NCT03894150","lead_sponsor":"Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.","biomarkers":" TNFRSF8","pipe":"","alterations":" ","tags":["TNFRSF8"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e F0002-ADC"],"overall_status":"Completed","enrollment":" Enrollment 45","initiation":"Initiation: 04/11/2019","start_date":" 04/11/2019","primary_txt":" Primary completion: 07/01/2020","primary_completion_date":" 07/01/2020","study_txt":" Completion: 03/12/2024","study_completion_date":" 03/12/2024","last_update_posted":"2024-05-14"}]